Last reviewed · How we verify
microsurfaced split thickness skin graft — Competitive Intelligence Brief
marketed
Wound Care / Dermatology
Biologic
Live · refreshed every 30 min
Target snapshot
microsurfaced split thickness skin graft (microsurfaced split thickness skin graft) — CellTherX. A microsurfaced split thickness skin graft is a processed autologous skin tissue product that provides a scaffold for wound healing and tissue regeneration.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| microsurfaced split thickness skin graft TARGET | microsurfaced split thickness skin graft | CellTherX | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- microsurfaced split thickness skin graft CI watch — RSS
- microsurfaced split thickness skin graft CI watch — Atom
- microsurfaced split thickness skin graft CI watch — JSON
- microsurfaced split thickness skin graft alone — RSS
Cite this brief
Drug Landscape (2026). microsurfaced split thickness skin graft — Competitive Intelligence Brief. https://druglandscape.com/ci/microsurfaced-split-thickness-skin-graft. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing